# Evercore Inc. (EVR)

> Source: Nexqual · https://nexqual.com/EVR · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Evercore Inc. (EVR), nexqual.com/EVR" · informational, not investment advice.

**Price:** USD 255.39 (+1.34% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 255.39 · day 246.75–256.35 · 52w 245.47–388.71 · market cap null · NYQ

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $4.74B, net income $745M (15.7% margin), free cash flow $1.63B (SEC filings).
- 1 of 80 tracked superinvestors hold EVR (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $2.7M; 1 not under a Rule 10b5-1 plan ($2.7M); 1 by opportunistic insiders (1 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.18 on a 1–5 scale) (11 analysts), mean target USD 332.2 (range 285–375).
- Total return with dividends: 1Y -18.7% vs S&P 500 +14.9%; 5Y +74.3% vs S&P 500 +80.3%.
- Next earnings: 2026-10-28, EPS estimate USD 2.48, revenue estimate $926M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $3.31B | $2.78B | $2.44B | $3.00B | $3.88B | $4.74B |
| Net income | $740M | $477M | $255M | $378M | $592M | $745M |
| EPS (diluted) | $17.08 | $11.61 | $6.37 | $9.08 | $14.05 | — |
| Free cash flow | $1.36B | $508M | $438M | $958M | $1.18B | $1.63B |
| Net margin | 22.4% | 17.1% | 10.5% | 12.6% | 15.3% | 15.7% |
| Revenue growth | +44.7% | -16.0% | -12.1% | +22.7% | +29.5% | — |
| Cash + short-term investments | $2.36B | $2.10B | $2.03B | $2.39B | $3.01B | — |
| Total debt | $376M | $372M | $374M | $336M | $540M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)

P/E at fiscal year-ends: Dec 2025 24.2x, Dec 2024 30.5x, Dec 2023 26.8x.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold EVR. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | <0.01% | $1.4M | Added +1.5% |

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-11 | Lalonde Timothy Gilbert | Chief Financial Officer | 7,808 | $2.7M | 18.3% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 2.18 on a 1–5 scale), 11 analysts; mean target USD 332.2 (low 285, high 375).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-08 | Morgan Stanley | Target lowered | Equal-Weight | $363 → $315 |
| 2026-10-07 | UBS | Target lowered | Neutral | $359 → $318 |
| 2026-10-01 | Goldman Sachs | Target lowered | Buy | $377 → $331 |
| 2026-08-03 | BMO Capital | Target lowered | Market Perform | $390 → $338 |
| 2026-07-30 | UBS | Target raised | Neutral | $350 → $359 |
| 2026-07-30 | Morgan Stanley | Target lowered | Equal-Weight | $376 → $363 |
| 2026-07-30 | Keefe, Bruyette & Woods | Target lowered | Outperform | $390 → $375 |
| 2026-07-10 | Keefe, Bruyette & Woods | Target raised | Outperform | $375 → $390 |
| 2026-07-08 | UBS | Target raised | Neutral | $330 → $350 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | -18.7% | +74.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -18.8% | +11.7% |
| Volatility (annualized) | 37.9% | 35.7% |
| Max drawdown | -34.8% (Jan 2026→Oct 2026) | -47.7% (Oct 2021→Sep 2022) |

## Peers (Capital Markets)
GLXY (Galaxy Digital Inc.) USD 15.29 -9.69% · SF (Stifel Financial Corporation) USD 67.85 +2.17% · JEF (Jefferies Financial Group Inc.) USD 45.64 +1.35% · HLI (Houlihan Lokey, Inc.) USD 133.24 +3.78% · HUT (Hut 8 Corp.) USD 63.97 -10.63% · IREN (IREN LIMITED) USD 25.51 -8.37%

## More
Full page: https://nexqual.com/EVR · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in EVR's own 10-K filed 2026-02-20 (https://www.sec.gov/Archives/edgar/data/1360901/000162828026010273/evr-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Glisco Partners II | "We maintain a limited partner's interest in Glisco Partners II, L.P. ("Glisco II"), Glisco Partners III, L.P. ("Glisco III") and Glisco Capital Partners IV, L.P. ("Glisco IV", and together with Glisco II and Glisco III, …" |
| Partner | Glisco Partners | "We maintain a limited partner's interest in Glisco Partners II, L.P. ("Glisco II"), Glisco Partners III, L.P. ("Glisco III") and Glisco Capital Partners IV, L.P. ("Glisco IV", and together with Glisco II and Glisco III, …" |
| Partner | Glisco Partners III | "We maintain a limited partner's interest in Glisco Partners II, L.P. ("Glisco II"), Glisco Partners III, L.P. ("Glisco III") and Glisco Capital Partners IV, L.P. ("Glisco IV", and together with Glisco II and Glisco III, …" |
| Partner | Glisco Capital Partners IV | "We maintain a limited partner's interest in Glisco Partners II, L.P. ("Glisco II"), Glisco Partners III, L.P. ("Glisco III") and Glisco Capital Partners IV, L.P. ("Glisco IV", and together with Glisco II and Glisco III, …" |

Other companies that name EVR in their own reports (relationship from EVR's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | KNOT Offshore Partners LP (KNOP) | 20-F 2026-04-17 | "The Conflicts Committee of the Partnership's Board, which is comprised of only non-KNOT-affiliated directors, retained Evercore Group L.L.C., Richards, Layton & Finger, P.A. and IGB Group as independe…" |
| partner | Jasper Therapeutics, Inc. (JSPR) | 10-K 2026-03-30 | "February 2024, the Company entered into an underwriting agreement with Cowen and Company, LLC and Evercore Group L.L.C., as the representatives" |
| partner | FRACTYL HEALTH, INC. (GUTS) | 10-K 2026-03-24 | "On September 26, 2025, we entered into an underwriting agreement with BofA Securities, Inc. and Evercore Group L.L.C., as representatives of several underwriters, pursuant to which we issued and sold …" |
| partner | AN2 Therapeutics, Inc. (ANTX) | 10-K 2026-03-17 | "In August 2023, the Company entered into an Underwriting Agreement with Cowen and Company, LLC, Leerink Partners LLC and Evercore Group L.L.C. as representatives of several underwriters to issue and s…" |
| partner | Global Ship Lease, Inc. (GSL) | 20-F 2026-03-16 | "On August 16, 2024, the Company entered into an equity distribution agreement with Evercore Group L.L.C. under which" |
| partner | Savara Inc (SVRA) | 10-K 2026-03-13 | "On July 6, 2021, the Company entered into a Sales Agreement with Evercore Group L.L.C. ("Evercore"), as sales agent (the "ATM Agreement"), permitting the Company to offer and sell up to an aggregate o…" |
| partner | Mineralys Therapeutics, Inc. (MLYS) | 10-K 2026-03-12 | "On September 2, 2025, we entered into an underwriting agreement with BofA Securities, Inc., Evercore Group L.L.C. and Goldman Sachs & Co. LLC as representatives of the several underwriters named there…" |
| partner | Atea Pharmaceuticals, Inc. (AVIR) | 10-K 2026-03-05 | "Expecting that the results of the HCV Phase 3 clinical development program will drive stockholder value and catalyze business development discussions, in November 2025, we concluded the formal engagem…" |
| partner | Definium Therapeutics, Inc. (DFTX) | 10-K 2026-02-26 | "On August 9, 2024, we entered into an underwriting agreement with Leerink Partners LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein, in connection with an of…" |
| partner | Viridian Therapeutics, Inc.\DE (VRDN) | 10-K 2026-02-26 | "In October 2025, we entered into an underwriting agreement with Jefferies LLC, Leerink Partners LLC, Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated related to the offer and sale of…" |
| partner | RED ROBIN GOURMET BURGERS INC (RRGB) | 10-K 2026-02-25 | "On November 10, 2025, The Company entered into the Distribution Agreement with Evercore, to establish an at-the-market equity offering program." |
| partner | FuboTV Inc. (FUBO) | 10-K 2025-03-03 | "On August 4, 2022, we entered into an at-the-market sales agreement with Evercore Group L.L.C., Citigroup Global Markets Inc., Morgan Stanley & Co. LLC and Needham & Company, LLC, as sales agents, und…" |

## Revenue by business segment (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Investment Banking & Equities | $936.2M | 93.8% | +18.8% |
| Investment Management | $23.7M | 2.4% | +14.4% |
| Total revenue | $998.5M | 100% | — |
The lines above cover 96.1% of total revenue.

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Advisory Fees | $775.6M | 77.7% | +11.2% |
| Underwriting Fees | $97.1M | 9.7% | +201.4% |
| Commissions & Related Revenue | $63.5M | 6.4% | +9.0% |
| Asset Management1 | $23.7M | 2.4% | +14.4% |
| Wealth Management | $23.7M | 2.4% | +14.4% |
| Total revenue | $998.5M | 100% | — |
The lines above cover 98.5% of total revenue.

## Company outlook (8-K filed 2026-07-29)

- "As of June 30, 2026, the Company expects to pay an aggregate of $318.5 million related to our deferred cash compensation program at various dates through 2030."
- "As a result, the Adjusted earnings presentation assumes that the allocation of earnings to Evercore LP's noncontrolling interest holders is substantially eliminated and is therefore subject to statutory tax rates of a C-Corporation under a conventional tax structure in the U.S. and that certain state and local taxes are reduced accordingly. – Presentation of Interest Expense."
- "As a result, the Adjusted earnings presentation assumes that the allocation of earnings to Evercore LP's noncontrolling interest holders is substantially eliminated and is therefore subject to statutory tax rates of a C-Corporation under a conventional tax structure in the U.S. and that certain state and local taxes are reduced accordingly."
- "(8) Assumes the exchange into Class A shares of substantially all Evercore LP Units and IPO related restricted stock unit awards in the Adjusted presentation."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $2.48 | $3.65 | -32.2% | $925.7M | 10 |
| Next quarter (ends 2026-12-31) | $4.97 | $5.56 | -10.6% | $1.33B | 9 |
| Current fiscal year (ends 2026-12-31) | $18.11 | $19.85 | -8.7% | $4.64B | 10 |
| Next fiscal year (ends 2027-12-31) | $20.83 | $23.27 | -10.5% | $5.25B | 10 |